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OBJECTIVE—Patients with diabetes have increased cardiovas-
cular risk. Atherosclerosis in these patients is often associated
with increased plaque macrophages and dyslipidemia. We hypoth-
esized that diabetic atherosclerosis involves processes that impair
favorable effects of lipid reduction on plaque macrophages.
RESEARCH DESIGN AND METHODS—Reversa mice are LDL
receptor–deﬁcient mice that develop atherosclerosis. Their ele-
vated plasma LDL levels are lowered after conditional knockout
of the gene encoding microsomal triglyceride transfer protein. We
examined the morphologic and molecular changes in atheroscle-
rotic plaques in control and streptozotocin-induced diabetic
Reversa mice after LDL lowering. Bone marrow–derived macro-
phages were also used to study changes mediated by hyperglycemia.
RESULTS—Reversa mice were fed a western diet for 16 weeks
to develop plaques (baseline). Four weeks after lipid normaliza-
tion, control (nondiabetic) mice had reduced plasma cholesterol
(277%), plaque cholesterol (253%), and plaque cells positive for
macrophage marker CD68+ (273%), but increased plaque colla-
gen (+116%) compared with baseline mice. Diabetic mice had
similarly reduced plasma cholesterol, but collagen content in-
creased by only 34% compared with baseline; compared with
control mice, there were lower reductions in plaque cholesterol
(230%) and CD68+ cells (241%). Diabetic (vs. control) plaque
CD68+ cells also exhibited more oxidant stress and inﬂammatory
gene expression and less polarization toward the anti-inﬂammatory
M2 macrophage state. Many of the ﬁndings in vivo were reca-
pitulated by hyperglycemia in mouse bone marrow–derived
macrophages.
CONCLUSIONS—Diabetes hindered plaque regression in ath-
erosclerotic mice (based on CD68+ plaque content) and favorable
changes in plaque macrophage characteristics after the reduction
of elevated plasma LDL. Diabetes 60:1759–1769, 2011
T
ype 1 and 2 diabetic patients have earlier onset
and more extensive atherosclerosis than similar
aged nondiabetic patients. Moreover, the pres-
ence of diabetes is associated with more coro-
nary events and worse clinical outcomes (1,2). This might
reﬂect the presence of plaques that are more vulnera-
ble to rupture. Indeed, careful pathologic assessment of
atherosclerotic plaques shows that diabetes is associated
with more macrophages and lipid-rich areas (3), features
of unstable plaques. Although studies in type 1 diabetes
have established that more intensive glucose management
reduces cardiovascular events (4), clinical trial data in
type 2 diabetes remain controversial. The reasons for this
are debated and might reﬂect differences in pathobiology,
therapy, or extent of disease when the trials were initiated.
Current clinical practice to reduce cardiovascular risk in
diabetes includes plasma LDL lowering, which should not
only retard the progression of atherosclerosis, but also
promote its regression. Given the importance of macro-
phages in plaque development and pathology (5), the effects
of plasma lipid changes on these cells have been an active
area of research. In our own studies, we have shown in
a surgical transplant model that the content of monocyte-
derived CD68+ cells (mostly macrophages and macrophage
foam cells) in mouse atherosclerotic plaques declined
quickly in normolipidemic conditions. Furthermore, some
plaque CD68+ cells were shown to emigrate to regional and
systemic lymph nodes in a process dependent on the che-
mokine (C-C) motif receptor-7 (CCR7) (6).
It is now recognized that macrophage phenotypes vary
(7). Inﬂammatory macrophages, often referred to as M1
macrophages, are involved in pathogen recognition and
inﬂammatory cytokine secretion. Tissue repair is thought to
be mediated by M2, or alternatively activated, macrophages
(8). Both M1 and M2 macrophages, as well as monocyte-
derived dendritic cells, are found in human and mouse
atherosclerotic plaques (9,10), with the M1 type thought to
play a critical role in the progression of atherosclerosis.
In the current report, we have focused on whether the
diabetic state negatively inﬂuences the ability of plasma
lipid reduction to regress atherosclerotic plaques. Given
the importance of both the amount and the characteristics
of plaque macrophages to the disease process, we exam-
ined whether diabetes interfered with a reduction in the
content of macrophages or in their inﬂammatory state af-
ter the repression of hyperlipidemia. To accomplish this,
we turned to the Reversa mouse, in which the hyperlip-
idemia of the LDL receptor knockout (LdLr
2/2) mouse
can be reduced by the conditional inactivation of the mi-
crosomal triglyceride transfer protein gene (Mttp) (11).
Atherosclerosis was allowed to develop in Reversa mice
before they were made diabetic by streptozotocin (STZ)
injection to avoid effects of diabetes on plaque pro-
gression. Hyperlipidemia then was repressed by Mttp ab-
lation in both normoglycemic and diabetic mice. The
morphometric and histologic changes in the plaques, as well
as the molecular changes in CD68+ cells laser-captured
from the plaques, were then determined. Studies of the
effects of hyperglycemia on cultured bone marrow–
derived macrophages (BMDMs) were performed to ex-
tend the results.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Animals. Reversa mice (LdLr
2/2Apob
100/100Mttp
ﬂ/ﬂMx1-Cre
+/+) have been de-
scribed previously (11). Animals were cared for in accordance with the Na-
tional Institutes of Health guidelines and the New York University Institutional
Animal Care and Use Committee (Protocol 090908). At 4 weeks of age, pups
were weaned and placed on a western diet (Catalog no. 100244; Dyets Inc.,
Bethlehem, PA). After 15 weeks on the diet, some mice were given intra-
peritoneal injections of citrate buffer or, to mimic type 1 diabetes, low-dose
STZ (50 mg/kg; Sigma-Aldrich, St. Louis, MO) (12) according to the protocol of
the National Institutes of Health-funded Animal Models of Diabetic Compli-
cations Consortium (www.AMDCC.org). After citrate or STZ injections, the
group of nontreated mice (baseline group) was killed, and aortic roots and
arches were harvested. To reverse the hyperlipidemic lipid proﬁle by condi-
tionally inactivating the Mttp gene, both citrate- and STZ-treated mice
(regression and regression/STZ groups, respectively) were given intraperi-
toneal injections of polyinosinic polycytidylic RNA (pIpC) (Sigma-Aldrich)
15 mg/kg every other day for a total of four injections (11). The mice were also
switched to a standard chow diet to obtain maximal lipid-lowering effects. All
mice were killed 4 weeks after the last injection of pIpC. At the time of tissue
harvest, blood was collected via heart puncture for plasma analyses.
Cell culture. BMDMs were prepared from monocytes isolated from the tibia
and femur of 6–8-week-old Reversa mice as previously described (13).
Typically, cells were incubated for 7 days in Dulbecco’sm o d i ﬁed Eagle’s
medium (DMEM), 10% FBS, and 10 ng/mL macrophage colony-stimulating
factor (PeproTech, Inc., Rocky Hill, NJ) in normal D-glucose (100 mg/dL) to
promote their differentiation into unactivated (M0) macrophages. Cells
were then incubated in DMEM containing “normal D+L-glucose” (100 mg/dL
D-glucose + 350 mg/dL L-glucose) 6 interleukin (IL)-4 (10 ng/mL; PeproTech,
Inc.) or high D-glucose (450 mg/dL D-glucose) 6 IL-4 (10 ng/mL) in 1% FBS
for 24 h. The L-glucose was used to control for changes in osmolarity (see
RESULTS for more details). IL-4 was used as a standard polarizer of macro-
phages to the M2 state (13).
Plasma measurements and lipoprotein analyses. Total cholesterol, free
fatty acid, and triglyceride concentrations were measured using colorimetric
assays (all kits from Wako Diagnostics, Richmond, VA). The distribution of
lipids within the plasma lipoproteins was determined by fractionating the
plasma (pooled from ﬁve mice per group) using fast protein liquid chroma-
tography followed by a colorimetric assay for total cholesterol (11). For glu-
cose measurements, mice were fasted for 4 h, and glucose in tail blood was
measured using a blood glucose monitor (TrueTrack Smart System, Nipro
Diagnostics, Inc., Fort Lauderdale, FL). IL-6 and monocyte chemoattractant
protein-1 (MCP-1) were measured using an ELISA kit from eBiosciences (San
Diego, CA) according to the manufacturer’s protocol.
Histochemical analyses of tissues and cells. Aortic roots were harvested
fromeachmouseafterperfusion withanRNAseinhibitor(Ambion,Austin,TX),
frozen in optimal cutting temperature compound, and serial-sectioned at
a thickness of 6 µm onto glass slides. For immunostaining of CD68 (macro-
phage marker), slides were ﬁxed in 100% acetone and exposed to primary anti-
CD68 antiserum (Serotec, Raleigh, NC), followed by biotinylated secondary
antibody, with visualization using a kit from Vector Laboratories, Inc. (Bur-
lingame, CA).
Actin was visualized by ﬂuorescein isothiocyanate (FITC)-conjugated anti-
b-actin (Abcam, Cambridge, MA) or by FITC-phalloidin (Invitrogen, Carlsbad,
CA). Tubulin was detected by antitubulin (Sigma-Aldrich) and visualized by
probing with FITC-conjugated anti-rabbit secondary antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA). Microscopic images of
aortic root sections were digitized, and morphometric measurements were
performed using Image Pro Plus software (14).
For collagen quantiﬁcation, slides were stained with picrosirius red as
previously reported (14), and collagen was visualized using polarizing light
microscopy (15). Tissue content of neutral lipids (which in plaques mainly
consists of cholesteryl ester) and free cholesterol were detected by Oil-Red O
(Sigma-Aldrich) and ﬁlipin (Sigma-Aldrich) staining, respectively, using sec-
tions ﬁxed in 10% formalin and stained as described previously (16,17). Slides
were mounted in Vectashield containing DAPI for nuclear staining (Vector
Laboratories).
Frozen aortic root sections were stained for oxidative stress using dihy-
droethidium (Invitrogen) as described previously (18). BMDMs were incubated
for 24 h in normal D-glucose (100 mg/dL D-glucose + 350 mg/dL L-glucose) or
high D-glucose medium (450 mg/dL D-glucose). The cells were then washed
and treated with MitoSOX (Molecular Probes, Eugene, OR) following the
manufacturer’s protocol. The cells were subjected to the C6 Flow Cytometer
(Accuri, Ann Arbor, MI), and cells with MitoSOX staining were observed in the
phycoerythrin channel. Another group of cells from the above conditions were
plated on chamber slides and counterstained with DAPI. The staining was
quantiﬁed using Image Pro Plus software.
Laser capture microdissection and quantitative (real-time) PCR. CD68+
cells were selected from atherosclerotic plaques by laser capture micro-
dissection (LCM). All LCM procedures were performed under RNase-free
conditions. Aortic root sections were stained with hematoxylin-eosin as
previously described (19,20). Foam cells were then identiﬁed under a micro-
scope and veriﬁed by positive CD68 staining. For each animal, CD68+ cells
were captured from 50–60 frozen sections. After LCM, RNA was isolated using
the PicoPure Kit (Molecular Devices, Inc., Sunnyvale, CA), and quality and
quantity were determined using an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA). RNA was converted to cDNA and ampliﬁed using
the WT-Ovation Pico RNA Ampliﬁcation Kit (NuGEN, San Carlos, CA). RT-
PCR was performed using a 7300 RT-PCR System (Applied Biosystems,
Carlsbad, CA), and data were analyzed using standard curves generated for
each set of primers/probe (Supplementary Table 1).
Functional studies in vitro. For arginase activity, we measured urea for-
mation according to the manufacturer’s protocol (QuantiChrom, BioAssay
Systems, Hayward, CA). In brief, media were collected 24 h after treatment of
BMDMs with high D-glucose + IL-4 or normal glucose (100 mg/dL D-glucose +
350 mg/dL L-glucose) + IL-4. Urea levels were measured and adjusted by vol-
ume and protein concentration.
Cell spreading. BMDMs were incubated for 24 h in normal D-glucose (100
mg/dL D-glucose + 350 mg/dL L-glucose) or high D-glucose (450 mg/dL) me-
dium. Cells were then replated onto collagen-coated chamber slides (Fisher
Scientiﬁc, Waltham, MA) and incubated for 2 h in normal or high glucose
medium. Cells were stained for actin using FITC-phalloidin, and cell area was
quantiﬁed using Image Pro Plus software.
Statistical analysis. Data are expressed as the mean 6 SEM and were ana-
lyzed using the two-tailed Student t test or one-way ANOVA followed by
Bonferroni’s multiple comparison test. P , 0.05 was considered to be signif-
icant. All tests were performed using the Prism software (GraphPad Software,
Inc., La Jolla, CA).
RESULTS
Plasma cholesterol and lipoprotein levels. The study
protocol is diagrammed in Fig. 1A. Reversa mice were
weaned and then fed a western diet for 16 weeks to allow
advanced plaques to develop. Mice were separated into
three groups: baseline mice killed at 16 weeks and two
regression groups (regression and the diabetic regression/
STZ) that were injected with pIpC to conditionally delete
the Mttp gene to reduce plasma lipid levels (11). The
regression/STZ mice were administered an intraperitoneal
injection of STZ for 5 days preceding pIpC treatment. This
protocol did not increase the glucose or the plasma lipids
during the 1-week interval between the STZ and pIpC
treatments (data not shown). Before pIpC, total plasma
cholesterol (Fig. 1B) and fasting glucose levels (Fig. 1C)
were similar in the mice assigned to the baseline and the
two regression groups: Levels of plasma cholesterol aver-
aged ;670 mg/dL and glucose ;125 mg/dL in all groups.
Fast protein liquid chromatography analysis of plasma
showed the majority of cholesterol to be in the LDL frac-
tion (Fig. 1D). Four weeks after pIpC injections, regression
and regression/STZ mice had similarly reduced plasma
total cholesterol levels (134 6 6 vs. 133 6 8 mg/dL) (Fig.
1B), without evidence of remnant lipoproteins in the di-
abetic mice (Fig. 1D). Regression/STZ mice had a plasma
glucose level fourfold greater than that of regression mice
(480 6 26 vs. 122 6 7 mg/dL) (Fig. 1C). Other lipid
parameters, including free fatty acids and triglycerides,
were not different between the different groups (Fig. 1E
and F). There was a 16.5% decrease in weight in the
regression/STZ group compared with the regression group
(Fig. 1G).
We also examined general inﬂammation at the end of the
study by measuring IL-6 and MCP-1 in plasma from both
regression and regression/STZ mice. Regression/STZ mice
have similarly low levels of IL-6 and MCP-1 compared with
regression and saline-injected (negative control) groups
(Supplementary Fig. 1), whereas lipopolysaccharide-treated
IMPAIRED ATHEROSCLEROSIS REGRESSION IN DIABETES
1760 DIABETES, VOL. 60, JUNE 2011 diabetes.diabetesjournals.orgFIG. 1. Experimental design and plasma lipid and glucose data. A: Reversa mice were placed on a western diet for 16 weeks. A group of animals (n =
10) was killed at 16 weeks of western diet and used as the baseline group. Two other groups of animals (n = 10 each) received citrate buffer or STZ
at 15 weeks. At 16 weeks, regression and regression/STZ groups received pIpC injections and were switched to a chow diet. Animals were killed 4
weeks after the last pIpC injection. Plasma cholesterol (B) and glucose levels (C) were measured at the 16-week time point and at the end of the
experiment. D: Plasma samples were also analyzed by fast protein liquid chromatography (FPLC) using pooled plasma from ﬁve animals. Total
cholesterol was measured in each fraction. Plasma triglycerides (E), nonesteriﬁed free fatty acids (F), and body weight (G) were also measured at
the end of the experiment. Data (mean 6 SEM) were analyzed using one-way ANOVA followed by Bonferroni’s multiple comparison test (B)o r
Student two-tailed t test (C and G). P < 0.05 values were considered to be signiﬁcant, **P < 0.01 and ***P < 0.001.
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IL-6 and MCP-1.
Changes in plaque area and composition in regression
and regression/STZ mice after the reduction of hyper-
lipidemia. Diabetes signiﬁcantly impaired the decrease in
plaque CD68+ cells after hyperlipidemia was reduced (Fig.
2A and C). Compared with baseline mice, there was a 73%
decrease in plaque CD68+ cells in the regression group. In
contrast, in the regression/STZ group, the decrease in
plaque CD68+ cells was only 41%.
It is surprising that despite the differences in CD68+ cell
content, there was little variation in the absolute area of
aortic root plaques in regression (0.46 6 1m m
2)a n d
regression/STZ groups (0.42 6 0.1 mm
2 compared with
FIG. 2. Diabetic mice have increased CD68+ cell and decreased collagen content compared with nondiabetic mice after plasma lipid reduction.
Aortic roots from baseline and the two regression groups were sectioned, ﬁxed, and stained for CD68+ cells. A: CD68+ cells as the percentage of
plaque area. B: Plaque areas quantiﬁed by Image Pro Plus software. C: Sample pictures of CD68 staining are shown for each group. D:C o l l a g e n
content was determined by picrosirius red staining using both bright ﬁeld and polarized light microscopy and quantiﬁed by Image Pro Plus software.
Data are presented as the percentage of lesion area. E: Representative sample pictures of collagen staining are shown for each group. Each group
contains 8–10 animals. Data (means 6 SEM) were analyzed using one-way ANOVA followed by Bonferroni’s multiple comparison test. P values are
shown as *P < 0.05 and ***P < 0.001. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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2, Fig. 2B). We hypothesized
that the composition of extracellular matrix was altered
during the regression process. As shown in Fig. 2D and E,
the collagen content was increased by 100% in the re-
gression group and by only 37% in the regression/STZ
group compared with the baseline group.
Diabetes also impaired the decrease in plaque lipid
content during regression. In the baseline group, 20 and
37% of total plaque area were positive for neutral lipids
and free cholesterol, respectively (Fig. 3A–D). The
neutral lipid area decreased to ;5% of the total plaque
area in the regression group, but was twice that in
the regression/STZ group (;10%). The free cholesterol
area decreased from 37% in the baseline group to 17%
in the regression group and to 26% in the regression/STZ
group.
FIG. 3. Effects of diabetes on the lipid content of aortic root sections after plasma lipid reduction. Aortic roots were sectioned, ﬁxed, and stained
for neutral lipids (presumably cholesteryl esters) using Oil-Red O or for free cholesterol using ﬁlipin. The stained areas were quantiﬁed by Image
Pro Plus software. Oil-Red O–positive areas (A) and free cholesterol (blue staining) (B) are quantiﬁed and presented as the percentage of total
plaque area. Sample pictures of each lipid stain are shown for all experimental groups in C and D. In addition to ﬁlipin staining, immunostaining for
CD68 (red) and b-actin (green) are also shown (D). Data (means 6 SEM) were analyzed using one-way ANOVA followed by Bonferroni’s multiple
comparison test. P < 0.05 values were considered to be signiﬁcant, *P < 0.05 and ***P < 0.001. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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reduction of hyperlipidemia. The expression of genes
associated with cell stress and inﬂammation from plaque
laser-captured CD68+ cells tended to be lower in the re-
gression group compared with the baseline group (Table 1).
In particular, the regression group had statistically sig-
niﬁcantly lower expression levels of S100a8, matrix
metalloproteinase-2 (MMP-2), inducible nitric-oxide syn-
thase, and IL-1. It is noteworthy that the statistical sig-
niﬁcance of the regression-associated decreases was lost
in the regression/STZ group, with the mean values for
these and the other genes in the regression/STZ group
either intermediate between those in the other two
groups or, in the case of C/EBP homologous protein
(CHOP), even higher than that in the baseline group.
Markers for alternatively activated M2 macrophages
(Arg1, Arg2, Fizz, and IL-10) (21) all showed trends to-
ward an increase in the regression group compared with
the baseline group, with the suggestion that diabetes
blunted the effects of plasma lipid reduction on these
markers.
In a transplant model of regression, the reduction in
plaque CD68+ cells was dependent on their emigration
through a pathway dependent on CCR7, a chemokine re-
ceptor that mediates migration of certain types of leuko-
cytes (6). In the Reversa model, CCR7 expression was
also induced by the reduction in hyperlipidemia in the
regression group compared with the baseline group (Table
1). In contrast, in the regression/STZ group, CCR7 ex-
pression was suppressed compared with the baseline and
regression groups, supporting the idea that one explana-
tion for the greater content of plaque CD68+ cells in the
regression/STZ versus the regression group (Fig. 2A and C)
is that diabetes impeded their emigration.
Hyperglycemia causes changes in macrophage gene
expression and in the ability of IL-4 to promote
polarization to the M2 phenotypic state. The results
above suggested that diabetes may interfere with changes
in the inﬂammatory state and the M2 polarization of
macrophages in a regression environment. To simulate the
phenomena observed in vivo, we tested in BMDMs
whether the hyperglycemic level achieved in the diabetic
mice similarly increased inﬂammatory gene expression or
interfered with the potency of IL-4, a commonly used in-
ducer of the M2 state. First, BMDMs in the M0 (un-
polarized) state were cultured in normal D-glucose (100
mg/dL) and then switched to a high D-glucose (450 mg/dL)
medium or a normal D-glucose medium osmotically
matched to the high D-glucose medium by the addition of
L-glucose (100 mg/dL D-glucose + 350 mg/dL L-glucose;
“normal + L-glucose”). In the high D-glucose medium, there
were increased mRNA levels of CHOP, MMP-2, MMP-9,
S100a8, inducible nitric oxide synthase, vascular cell ad-
hesion molecule-1, and intercellular adhesion molecule-1
(Table 2), consistent with the results that proatherogenic
factors tended to be higher in plaque CD68+ cells from
regression/STZ versus regression mice (Table 1). Unlike
the LCM data (Table 1), CCR7 mRNA was unaffected by
hyperglycemia.
We next examined whether hyperglycemia interfered
with IL-4 to polarize macrophages to the alternatively ac-
tivated M2 state. In high D-glucose (vs. normal D+L-glucose)
medium, IL-4–treated BMDMs had decreased expression
of two standard markers of the M2 state (Fig. 4A and B).
To extend these data, we also assessed arginase functional
activity by measuring urea production, and the pattern was
consistent with the mRNA data (Fig. 4C).
Because arginase activity is positively associated with
collagen production (22,23), we also measured collagen in
cultures of IL-4–treated BMDMs under normo- (normal
D+L-glucose) and hyperglycemic (high D-glucose) condi-
tions. As shown in Fig. 4D, hyperglycemia resulted in an
;70% reduction in collagen.
TABLE 1
Gene expression analysis of laser-captured plaque CD68+ cells
Baseline Regression
Regression/
STZ
Stress/inﬂammation
CHOP 0.74 6 0.22 0.14 6 0.12 1.23 6 0.64†
S100a8 0.72 6 0.16 0.12 6 0.04* 0.35 6 0.14
MMP-2 2.26 6 0.40 0.19 6 0.25* 1.58 6 0.25
MMP-9 1.38 6 0.57 0.55 6 0.41 1.22 6 0.68
ICAM-1 1.28 6 0.71 0.78 6 0.37 1.75 6 0.56
VCAM-1 1.98 6 0.07 1.47 6 0.51 2.34 6 1.07
iNOS 0.16 6 0.06 0.02 6 0.01* 0.05 6 0.03
IL-1 0.95 6 0.25 0.08 6 0.03* 0.34 6 0.12
Migration
CCR7 1.19 6 0.31 8.37 6 3.43* 0.12 6 0.05†
M2/anti-inﬂammatory
Arg1 10.7 6 4.32 32.4 6 18.2 17.0 6 3.42
Arg2 0.15 6 0.02 0.41 6 0.12 0.05 6 0.05
Fizz 0.21 6 0.13 0.57 6 0.18 0.24 6 0.15
IL-10 0.27 6 0.10 1.62 6 0.56 1.24 6 0.34
Data (mean 6 SEM) were analyzed by one-way ANOVA followed by
Bonferroni’s multiple comparison test. CD68+ cells from aortic roots
of Reversa mice were isolated using LCM (each group contained 8–10
animals). mRNA was then isolated and subjected to analyses by
RT-PCR. mRNA levels are presented as relative levels normalized
to 28S (loading control). ICAM-1, intercellular adhesion molecule-1;
iNOS, inducible nitric-oxide synthase; VCAM-1, vascular cell adhe-
sion molecule-1. *P , 0.05 was considered to be signiﬁcant compared
with baseline. †P , 0.05 was considered to be signiﬁcant compared
with regression.
TABLE 2
Gene expression analysis of BMDMs
Normal D+L-glucose High D-glucose
Stress/inﬂammation
CHOP 1.00 6 1.12 1.79 6 0.15*
S100a8 1.00 6 0.07 1.86 6 0.17*
MMP-2 1.00 6 0.07 1.33 6 0.08*
MMP-9 1.00 6 0.11 2.27 6 0.24*
ICAM-1 1.00 6 0.02 2.94 6 0.14*
VCAM-1 1.00 6 0.14 4.45 6 0.35*
iNOS 1.00 6 0.18 2.45 6 0.17*
Migration
CCR7 1.00 6 0.15 1.69 6 0.42
Data (mean 6 SEM) were analyzed using a Student two-tailed t test.
For each experiment, BMDMs were pooled from two to three Reversa
animals at 6–8 weeks of age. BMDMs were maintained in culture me-
dium containing macrophage colony-stimulating factor (10 ng/mL) for
7 days and then treated with medium containing high D-glucose (450
mg/dL) or normal D+L-glucose (100 mg/dL D-glucose + 350 mg/dL
L-glucose) for 24 h. RT-PCR was performed as described in RESEARCH
DESIGN AND METHODS, and 28S RNA was used as a loading control. The
results are from two experiments performed in triplicate. ICAM-1, in-
tercellular adhesion molecule-1; iNOS, inducible nitric-oxide synthase;
VCAM-1, vascular cell adhesion molecule-1. *P , 0.05 was considered
to be signiﬁcant.
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morphology of BMDM. Oxidative stress has been shown
to increase macrophage spreading/adhesion and to reduce
cell migration (24,25). These effects led to increased ar-
terial intima macrophage retention in an in vivo model
(25). Because hyperglycemia (26,27) and hyperlipidemia
(28) increase cellular oxidative stress (29,30), we exam-
ined levels of reactive oxygen species (ROS) in the plaques
in the three groups. As shown in Fig. 5A, there was a sig-
niﬁcant reduction in ROS levels in the regression group
FIG. 4. Hyperglycemia blunts macrophage polarization in vitro by IL-4. For each experiment, BMDMs were pooled from two to three Reversa
animals and differentiated into M0 (unactivated) macrophages. The cells were then treated with or without IL-4 (to induce M2 polarization) in
normal D+L-glucose (100 mg/dL D-glucose + 350 mg/dL L-glucose) or high D-glucose (450 mg/dL) for 24 h. RT-PCR was performed, and 28S mRNA was
used as a normalizing variable. Results shown are for arginase 1 (A) and Fizz (B). C: Arginase functional activity was measured by urea production
according to the manufacturer’s protocol (QuantiChrom; BioAssay Systems, Hayward, CA). D: Collagen content of cultured BMDM treated with IL-4
(10 ng/mL) for 48 h in normal or high glucose was determined by picosirius red staining and quantiﬁed using polarized light microscopy. Stained
areas were quantiﬁed by Image Pro Plus software. Data (means 6 SEM) were analyzed using one-way ANOVA followed by Bonferroni’s multiple
comparison test (A and B) or Student two-tailed t test (C and D). *P < 0.05 and ***P < 0.001 values were considered to be signiﬁcant. (A high-
quality color representation of this ﬁgure is available in the online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 60, JUNE 2011 1765FIG. 5. Hyperglycemia increased oxidative stress in vivo and in vitro, and altered macrophage morphology and cell spreading in vitro. A: Frozen
aortic root sections from baseline, regression, and STZ/regression mice were stained with dihydroethidium to assess oxidative stress. The area
stained was quantiﬁed by Image Pro Plus software, and representative images from the regression and regression/STZ groups are shown. B:
BMDMs were incubated with DMEM containing normal D+L-glucose (100 mg/dL D-glucose + 350 mg/dL L-glucose) or high D-glucose (450 mg/dL) for
24 h. Cellular oxidative stress was determined by staining suspended cells with MitoSOX (Molecular Probes). The cells were then subjected to
ﬂuorescence-activated cell sorter analysis (red = normal D-glucose and blue = high D-glucose) or replated on chamber slides and the staining
quantiﬁed using Image Pro Plus. C: BMDMs were also stained with tubulin, and the length and width were measured with Image Pro Plus software.
D: For spreading experiments, cells were treated as above and replated on collagen-coated slides for 2 h and then stained with FITC-phalloidin
following the manufacturer’s protocol (Invitrogen). Cell areas were determined using Image Pro Plus. Data (means 6 SEM) were analyzed using
one-way ANOVA followed by Bonferroni’s multiple comparison test (A) or Student two-tailed t test (B–D). *P < 0.05 and ***P < 0.001 values were
considered to be signiﬁcant. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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regression/STZ group.
Hyperglycemia also increased ROS content in BMDMs, as
determined by staining for H2O2 (Fig. 5B). Fluorescence-
activated cell sorter analysis also showed that BMDMs in-
cubated in high D-glucose had a 44% increase (vs. incubation
in normal D+L-glucose) in staining for H2O2 as determined
by mean ﬂuorescence (Fig. 5B).
Hyperglycemia also caused striking morphologic changes
in vitro. As shown in Fig. 5C and D, BMDMs incubated
in high D-glucose were signiﬁcantly larger, more spread,
and spindle-shaped than cells grown in normal D+L-glucose.
The differences in cell morphology were quantiﬁed by
measuring the length versus width, as well as the cell
area.
DISCUSSION
The development of atherosclerosis that culminates in
a clinical event is neither continuous nor unidirectional.
Especially within the setting of diabetes, arterial pathology
in humans likely ﬂuctuates with changes in risk factors,
such as dyslipidemia and hyperglycemia. It is currently
recommended that patients with diabetes be treated
aggressively for both of these risk factors to retard the
progression of coronary artery disease and, ideally, to
promote plaque regression. To simulate therapeutic LDL
lowering in a model of atherosclerosis, we have used
Reversa mice. By conditionally inactivating the Mttp gene,
hyperlipidemia can be dramatically reduced at any time in
these mice (11). In the current study, we have allowed
advanced plaques to develop in Reversa mice before
inactivating the Mttp gene. Concomitant with the re-
duction of hyperlipidemia, half of the mice were treated
with STZ to produce diabetes to study whether plaque
regression, as judged by the content of CD68+ cells, would
be impaired. After the reduction in hyperlipidemia, the
major effects of diabetes on plaques were the following: 1)
impaired decrease in the content of CD68+ cells and free
and esteriﬁed cholesterol; 2) increased expression in CD68+
cells of genes considered to be detrimental in atheroscle-
rosis and decreased enrichment of those associated with
the alternatively activated M2 state of macrophages; 3)r e -
duced accumulation of collagen; and 4) increased oxidant
stress. Furthermore, studies in vitro, in which BMDMs were
incubated in normoglycemic or hyperglycemic conditions,
recapitulated many of the ﬁndings in vivo.
We have previously observed that plaque regression in-
volved the emigration of CD68+ cells (6,31), which was
dependent on CCR7, a chemokine receptor that promotes
the migration of certain classes of leukocytes (32,33). In
this study, plaques from the regression/STZ group contained
more CD68+ cells than the regression group, consistent
with decreased expression of CCR7 in vivo (Table 1), al-
though hyperglycemia did not signiﬁcantly affect CCR7
expression in vitro. The increased cell spreading in vitro
(Fig. 5D) was also consistent with a decreased migratory
ability of cells in a hyperglycemic environment.
The effects of hyperglycemia on cell morphology may
also be related to migration, given the recent ﬁndings that
macrophages incubated in high glucose medium had in-
creased activity of the r-associated coiled–coil protein ki-
nase, a major participant in cytoskeletal reorganization
(34). Decreased CD68+ cell emigration in the regression/
STZ plaques would also be compatible with the slower
wound healing in patients with diabetes, attributed in part
to impaired chemotaxis of skin ﬁbroblasts (35,36). None-
theless, we cannot rule out the possibility that diabetes
also contributed to limiting the decrease in plaque CD68+
cell content after lipid lowering by increasing the inﬂux of
circulating monocytes into the plaque.
As noted above, despite equivalent plasma lipid lowering
in both regression groups, the plaque content of choles-
terol and cholesteryl ester was greater in the regression/
STZ group. This was likely related to there being more
CD68+ foam cells in these plaques, although there was
also the suggestion that there was more extracellular lipid
(Fig. 3). Another contributing factor may have been re-
duced levels of ATP-binding cassette transporters in the
macrophages of the diabetic mice (37).
Plaques of hyperlipidemic diabetic mice have been
reported to have increased inﬂammatory gene expression
(38), but whether this was due to effects on a per cell basis
or greater numbers of inﬂammatory macrophages could
not be distinguished. By using LCM, the present data
demonstrate that even in the absence of hyperlipidemia,
diabetes impairs the resolution of the inﬂammatory state in
individual cells, a characteristic shared with macrophages
in progressing plaques (39). Macrophages in the inﬂam-
matory state are often referred to as being M1, as opposed
to those with anti-inﬂammatory properties (40), termed
“M2,” although acceptance of this simple classiﬁcation is
controversial (41). Nonetheless, macrophages in human
and mouse atherosclerotic plaques display both M1 and
M2 markers (9,10).
In the context of plaque regression, there would be
considerable advantage to the polarization of CD68+ cells
to the M2 state, because they are known to promote
the remodeling of damaged tissue (42). In addition to the
impairment of the reduction of plaque CD68+ content,
another deleterious effect of diabetes may be the in-
terference with favorable changes in macrophage pheno-
type after plasma lipid reduction, based on the data in
Table 1 as reviewed in RESULTS.
The hyperglycemia, and not the insulin deﬁciency of
STZ-diabetes, exerted the strong independent and negative
effects on the phenotypic state of plaque CD68+ cells, as
supported by the studies in vitro. Gene expression changes
in the regression/STZ group were paralleled in BMDMs
incubated in medium containing the same glucose con-
centration as measured in the diabetic mice. In addition,
the potency of the standard M2 inducer, IL-4, was attenu-
ated by incubating the cells in hyperglycemic medium.
These results could not be explained by changes in os-
molarity and are unlikely caused by toxicity of hypergly-
cemia on BMDM (43).
It was also remarkable that, in the regression/STZ group,
there was less plaque collagen accumulation than in the
normoglycemic mice. This may have also been a reﬂection
of the effects of diabetes on macrophage polarization,
because M2 macrophages are known to promote collagen
synthesis (44). Other possible explanations include the
greater expression of matrix-degrading enzymes MMP-2
and -9 that we found in vivo, as well as effects on plaque
smooth muscle cells, a major source of collagen in the
arterial wall, although the number of such cells did not
vary between the regression and regression/STZ groups
(data not shown). Consistent with the data in vivo, BMDMs
incubated in hyperglycemic medium had reduced expres-
sion of M2 markers and collagen production.
As reviewed by Hirsch and Brownlee (45) and Brownlee
(46), an overarching feature of diabetic hyperglycemia
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the promotion of cellular oxidative stress. The effects of
oxidative stress include the release of proinﬂammatory
cytokines, such as IL-1 (47), from macrophages. This is
consistent with the present data under hyperglycemic
conditions in vivo and in vitro. In particular, the incubation
of BMDM in the high glucose medium increased ROS.
Even more signiﬁcantly, the plaques in the regression/STZ
group demonstrated increased oxidant stress despite the
reduction of hyperlipidemia, another known ROS-elevating
factor. Given that oxidant stress in the plaques of regression/
STZ mice approached the level in the plaques of baseline
mice (Fig. 5), the data suggest that hyperglycemia is an in-
ducer of ROS comparable in potency to hyperlipidemia.
Current treatment guidelines emphasize that optimal
care of the diabetic patient includes aggressive manage-
ment of their dyslipidemia. An animal model to clinically
simulate this scenario has been elusive, but the de-
velopment of the Reversa mouse has now allowed us to
conveniently test the effects of hyperglycemia on the
process of plaque regression after a dramatic reduction of
plasma LDL. In general, many of the beneﬁts on plaque
composition (fewer macrophages, more collagen) and
CD68+ cell phenotype (less inﬂammation, more M2-like
characteristics) after lipid reduction were attenuated in
the diabetic mice. Although there are many differences
between STZ-induced diabetic mice and patients with di-
abetes (typically type 2 diabetes mellitus), the present data
are consistent with clinical studies showing that the ab-
solute risk of myocardial infarction remains higher in
patients with diabetes even after statin therapy (48). The
molecular exploration of mouse models of atherosclerosis
regression may ultimately explain why this is the case.
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